col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: The Japanese Pharmacological Society

52 Results       Page 1

 [1] 
  original article Journal Date Title Authors All Authors
1 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Inactivation of leukocytes for prevention of severe COVID-19 Mutoh-Matsushita Akiko
2 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Depressive symptoms and cognitive dysfunction in Post Covid-19 Condition Noda Takamasa, Kaori Okabe, Yasunari Kanda, Motohiro Nishida
3 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Population analysis approaches for the spread of covid-19 pandemic in 150 countries Koshimichi Hiroki
4 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure Katsuki Wakayama, Kiichi Nakahira, Akihiko Tanaka, Yosuke Hukuda, Jing Zhao, Shin Ohta, et al. (+2)
5 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Early prediction of severe COVID-19 progression by a novel lung injury-related biomarker protein Arakawa Noriaki
6 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 The prediction of therapeutic targets and microRNA network in the coronavirus pathogenesis pathway Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, et al. (+2)
7 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Single cell multiomic analysis of PBMCs from SARS-COV-2 infected patients Mara Anais Llamas Covarrubias, Yasuha Kinugasa, Yutaka Suzuki, Yumiko Imai
8 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 ACE2-like carboxypeptidase B38-CAP suppresses severe acute lung injury induced by aspiration pneumonia and abdominal sepsis as well as SARS-CoV-2 infection Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Satoru Nirasawa, Jianbo An, Saori Takahashi, et al. (+2)
9 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Development of a SARS-CoV-2 infection model using human iPSC-derived intestinal epithelium Yamada Shigeru, Takamasa Noda, Kaori Okabe, Shota Yanagida, Motohiro Nishida, Yasunari Kanda
10 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Antiviral activity of curcumin and its analogs selected by artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells Hirotsugu Komatsu, Takeshi Tanaka, Zhengmao Ye, Ken Ikeda, Takao Matsuzaki, Tamotsu Shiroma, et al. (+3)
11 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Strategy for Development of Therapeutics for HIV/AIDS, Chronic Hepatitis B, and SARS-CoV-2/COVID-19 Hiroaki Mitsuya
12 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dec―25 Role of histone ubiquitination in SARS-CoV2 and influenza virus infection Kinugasa Yasuha, Midori Hoshizaki, Mara Llamas Covarrubias, Yumiko Imai
13 [GO] Folia Pharmacologica Japonica 2022―Oct―31 A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs Daiki Ousaka, Masahiro Nishibori
14 [GO] Folia Pharmacologica Japonica 2022―Jun―30 Treatment of COVID-19 Kazuhiro Yatera
15 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19 Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu Asaka, Mayumi Niiyama, et al. (+9)
16 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Development of Therapeutics for HIV/AIDS, CHB and COVID-19 Hiroaki Mitsuya
17 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Development of vaccines and therapeutics for COVID-19. Kiyama Ryuichi
18 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs Daiki Ousaka, Dengli Wang, Masahiro Nishiboli
19 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Human iPSC-based models to evaluate COVID-19 drugs Yasunari Kanda
20 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 PMDA's efforts to promote medical innovation in the coronavirus pandemic Yasuhiro Fujiwara
21 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 The coronavirus-related signaling pathway networks and prediction modeling with activity plots. Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, et al. (+2)
22 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Eco-pharma research focusing on ACE2-mediated SARS-CoV-2 entry Kato Yuri, Yasunari Kanda, Motohiro Nishida
23 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Characteristics of SARS-CoV-2 mRNA/LNP vaccines and their official verification Hanada Kentaro
24 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 SARS-CoV-2 research using stem cell and organ-on-a-chip technologies Takayama Kazuo
25 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Establishment of SARS-CoV-2 respiratory tract infection model in CAG promoter-driven hACE2 transgenic mice Utsumi Daichi, Masamitsu Asaka, Haruhiko Kamada, Satoshi Nagata, Yutaka Nakachi, Tomokazu Yamaguchi, et al. (+3)
26 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Development of artificial antibody against receptor binding domain of SARS-CoV-2 spike protein. Masahiro Oike, Hirotaka Takahashi, Tatsuya Sawasaki
27 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Role of ACE2 in COVID-19 Yumiko Imai
28 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Engineered ACE2 receptor has a potential for a new therapy of COVID-19 Yumi Itoh, Hajime Enatsu, Akira Takada, Toru Okamoto
29 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Development of COVID-19 drugs using human iPS cell technology Shigeru Yamada, Yasunari Kanda
30 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Eco-pharma research aimed at developing COVID-19 therapeutic agent Yuri Kato, Kazuhiro Nishiyama, Akiyuki Nishimura, Motohiro Nishida
31 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Drug screening for COVID-19 using supercomputer “Fugaku” Yasushi Okuno
32 [GO] Folia Pharmacologica Japonica 2021―Dec―31 COVID-19 drug candidate pipeline, an overview Hiroyuki Sugiyama
33 [GO] Folia Pharmacologica Japonica 2021―Dec―31 Remdesivir for COVID-19 Yasuhisa Fujita
34 [GO] Folia Pharmacologica Japonica 2021―Dec―31 Drug repositioning to combat COVID-19 using artificial intelligence system Norihisa Shindo, Hiroyoshi Toyoshiba
35 [GO] Folia Pharmacologica Japonica 2021―Dec―31 Contribution to development of remedies for COVID-19: focusing on Eritoran Kappei Tsukahara
36 [GO] Folia Pharmacologica Japonica 2021―Oct―31 Responses to the COVID-19 pandemic and its impacts on pharmacology education in the universities and colleges in Japan: nationwide emergency survey jointly conducted by the Physiological Society of Japan and the Japanese Pharmacological Society Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Satoshi Tanaka, Masabumi Minami
37 [GO] Folia Pharmacologica Japonica 2021―Apr―30 Therapeutic potential of nanocurcumin in COVID-19 Koji Teshima
38 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Construction of the multi-layer omics data generation / analysis platform that contributes to the precision medicine of COVID-19 Yumiko Imai
39 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Treatment of COVID-19 Kazuhiro Yatera
40 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Remdesivir for COVID-19 Yasuhisa Fujita
41 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 COVID-19 Drug Candidate Pipeline, An Overview Hiroyuki Sugiyama
42 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Masamitsu Asaka, Satoru Nirasawa, Mayumi Niiyama, et al. (+10)
43 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Nationwide Emergency Survey Results on the Response to COVID-19 Pandemic and Its Effect on Pharmacological Education Conducted in the Department of Pharmacology in Universities and Colleges Jointly by the Physiology Society of Japan and the Japanese Pharmacological Society. Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Tomoyuki Tanaka, Masabumi Minami
44 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Eco-pharma research aimed at developing COVID-19 therapeutic agent Kato Yuri, Motohiro Nishida
45 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Drug repositioning to combat COVID-19 using artificial intelligence system Norihisa Shindo, Hiroyoshi Toyoshiba
46 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Drug Screening for COVID-19 using Supercomputer "Fugaku" Yasushi Okuno
47 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Contribution to Development of Remedies for COVID-19: Focusing on Eritoran Kappei Tsukahara
48 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Investigation of genetic variants in SARS-CoV-2-interacting molecules of ACE2, TMPRSS2 and TLR3/7/8 across populations Lee Ji-Won, In-Hee Lee, Sek Won Kong, Tadahiro Iimura
49 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 Treatment to prevent the development of severe COVID-19 Yumiko Imai
50 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 In silico approaches to drug repositioning for COVID-19 at AMED-BINDS Takatsugu Hirokawa, Sekijima Masakazu, Shigenori Tanaka, Haruki Nakamura
51 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 Nonstructural proteins of Novel Coronavirus (SARS-CoV-2) Wataru Kamitani
52 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 The initial response of the laboratory diagnosis team to SARS-CoV-2 in Japan and the current situation Makoto Takeda
 [1] 

52 Results       Page 1



[de][en]

Last change 2023―Apr―13 19:50:14 UTC

© Daten-Quadrat 2022       Done in 0.005 sec